AUSTIN, Texas--(BUSINESS WIRE)--Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it is partnering with the Novagen brand of EMD Chemicals Inc. (EMD), a subsidiary of Merck KGaA (Merck) of Germany, to develop and distribute high-quality immunoassay products on the Luminex® xMAP® platform. Under the terms of the agreement, RBM is granting EMD/Merck exclusive distribution rights to the largest catalog of quantitative protein multiplex assays currently available.
